Mineralys Therapeutics Inc. (MLYS): Price and Financial Metrics
MLYS Price/Volume Stats
| Current price | $9.13 | 52-week high | $21.98 |
| Prev. close | $9.51 | 52-week low | $8.87 |
| Day low | $8.87 | Volume | 87,053 |
| Day high | $10.09 | Avg. volume | 192,026 |
| 50-day MA | $12.32 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 373.02M |
MLYS Stock Price Chart Interactive Chart >
Latest MLYS News From Around the Web
Below are the latest news stories about MINERALYS THERAPEUTICS INC that investors may wish to consider to help them evaluate MLYS as an investment opportunity.
Praxis Bioresearch Expands its Board of Directors with Appointment of Adam LevyAdam Levy Appointment to Board of Directors LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Praxis Bioresearch (“Praxis”), a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and neurodegenerative disorders with an initial focus on apathy in Alzheimer’s Disease, today announced the appointment of Adam Levy to its Board of Directors (the “Board”). Mr. Levy brings executive, financial and operational leadership experience in biopharmace |
Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne KarydasDaphne Karydas Daphne Karydas Glenn Sblendorio Glenn Sblendorio RADNOR, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointments of Daphne Karydas and Glenn Sblendorio to its Board of Directors (the Board). Ms. Karydas and Mr. Sblendorio bring execu |
Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023RADNOR, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton, and Chief Financial Officer and Chief Business Officer, Adam Levy, will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference in |
Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure (BP) with a well-tolerated profile – – Enhanced reduction in systolic BP seen in individuals with elevated body mass index (BMI) – – Robust trial design and results led to lorundrostat being first of new class, aldosterone synthase inhibitors, to start pivotal clinical program in hypertension – RADNOR, Pa., Sept. 10, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeu |
Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure (BP), including an enhanced response in individuals with elevated body mass index (BMI) – – Results simultaneously published in the Journal of the American Medical Association (JAMA) – – Pivotal clinical program for lorundrostat as a treatment of patients with uncontrolled and resistant hypertension ongoing, with topline data from Advance-HTN and Launch-HTN tr |
MLYS Price Returns
| 1-mo | -29.33% |
| 3-mo | N/A |
| 6-mo | -34.51% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...